Geron shares down 43% premarket

|About: Geron Corporation (GERN)|By:, SA News Editor

FDA puts Geron's (GERN) IND application for imetelstat on full clinical hold.  This stops the Phase 2 trial for essential thrombocythemia and the Phase 2 for multiple myeloma. It will probably delay the start of the Phase 2 for myelofibrosis.

Imetelstat may be toxic to the liver based on abnormal function tests.

Geron must determine if the effects are reversible upon cessation on the drug.